Login to Your Account



NewCo News

Axerion Seeks New Answers in Spinal Cord Injury, Alzheimer's

By Marie Powers
Staff Writer

Monday, January 28, 2013
Privately held Axerion Therapeutics Inc. hopes to translate two technologies exclusively licensed from Yale University into revolutionary therapeutics in a pair of indications – spinal cord injury (SCI) and Alzheimer's disease (AD) – that have bedeviled biotechs and big pharmas, alike.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription